Effect of Intensive Blood Pressure Control on Cardiovascular Remodeling in Hypertensive Patients with Nephrosclerosis
Autor: | Tamrat M. Retta, Muluemebet Ketete, Otelio S. Randall, Keith C. Norris, Kenneth Jamerson, Shichen Xu, Lawrence Y. Agodoa, Tom Greene, Velvie A. Pogue, Xuelei Wang, John Kwagyan |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2013 |
Předmět: |
Blood pressure control
medicine.medical_specialty Mean arterial pressure Article Subject medicine.drug_class Calcium channel blocker 030204 cardiovascular system & hematology Bioinformatics lcsh:RC870-923 Muscle hypertrophy 03 medical and health sciences 0302 clinical medicine Internal medicine medicine 030212 general & internal medicine biology business.industry Angiotensin-converting enzyme medicine.disease lcsh:Diseases of the genitourinary system. Urology 3. Good health Pulse pressure Nephrology Cardiology biology.protein business Nephrosclerosis Kidney disease Research Article |
Zdroj: | International Journal of Nephrology International Journal of Nephrology, Vol 2013 (2013) |
ISSN: | 2090-2158 2090-214X |
Popis: | Pulse pressure (PP), a marker of arterial system properties, has been linked to cardiovascular (CV) complications. We examined (a) association between unit changes of PP and (i) composite CV outcomes and (ii) development of left-ventricular hypertrophy (LVH) and (b) effect of mean arterial pressure (MAP) control on rate of change in PP. We studied 1094 nondiabetics with nephrosclerosis in the African American Study of Kidney Disease and Hypertension. Subjects were randomly assigned to usual MAP goal (102–107 mmHg) or a lower MAP goal (≤92 mmHg) and randomized to beta-blocker, angiotensin converting enzyme inhibitor, or calcium channel blocker. After covariate adjustment, a higher PP was associated with increased risk of CV outcome (RR = 1.28, CI = 1.11–1.47,P<0.01) and new LVH (RR = 1.26, CI = 1.04–1.54,P=0.02). PP increased at a greater rate in the usual than in lower MAP groups (slope ± SE: 1.08 ± 0.15 versus 0.42 ± 0.15 mmHg/year,P=0.002), but not by the antihypertensive treatment assignment. Observations indicate that control to a lower MAP slows the progression of PP, a correlate of cardiovascular remodeling and complications, and may be beneficial to CV health. |
Databáze: | OpenAIRE |
Externí odkaz: |